April 2015

New Product - FDGen

FDGen (fludeoxyglucose (F‑18)) injection (fludeoxyglucose [¹⁸F]) is indicated in positron emission tomography (PET) imaging for assessment of abnormal glucose metabolism to assist in the evaluation of malignancy in patients with known or suspected abnormalities found by other testing modalities, or in patients with an existing diagnosis of cancer. Fludeoxyglucose (F‑18) injection is indicated in PET imaging in patients with coronary artery disease and left ventricular dysfunction, when used together with myocardial perfusion imaging, for the identification of left ventricular myocardium with residual glucose metabolism and reversible loss of systolic function. Fludeoxyglucose (F‑18) injection is also indicated in PET imaging for the identification of regions of abnormal glucose metabolism associated with the foci of epileptic seizures. FDGen is available as a solution for injection containing approximately 6 GBq/mL of fludeoxyglucose (F‑18) in a 10 mL multidose vial (contained in a 25 mm lead pot) and a 30 mL multidose vial (contained in a 36 mm tungsten pot).

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au